Sign Up to like & get
recommendations!
0
Published in 2019 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2019.1340
Abstract: Key Points Question Was the implementation of the Transmucosal Immediate-Release Fentanyl (TIRF)–Risk Evaluation and Mitigation Strategy (REMS) associated with changes in prescribing of TIRF medications? Findings In this cohort study using interrupted times series analysis,…
read more here.
Keywords:
evaluation mitigation;
transmucosal;
risk evaluation;
mitigation strategy ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Applied Clinical Informatics"
DOI: 10.1055/s-0042-1758838
Abstract: Abstract Background Risk Evaluation and Mitigation Strategy (REMS) programs intend to improve medication safety but can add significant administrative burdens to providers and health systems. Various stakeholders have made efforts to use technology to improve…
read more here.
Keywords:
risk evaluation;
review;
rems programs;
scoping review ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "PLOS Medicine"
DOI: 10.1371/journal.pmed.1004190
Abstract: In an analysis of risk evaluation and mitigation strategies for teratogenic drugs, Ameet Sarpatwari, Beatrice Brown and Aaron Kesselheim explore the variation in primary and secondary prevention measures.
read more here.
Keywords:
risk evaluation;
analysis risk;
teratogenic drugs;
mitigation strategies ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-1475
Abstract: For drugs with enhanced serious safety risks, Risk Evaluation and Mitigation Strategy (REMS) may be required. Pexidartinib is approved for treatment of adult symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional…
read more here.
Keywords:
risk evaluation;
cell tumor;
giant cell;
mitigation strategy ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines10081284
Abstract: Niclosamide, an FDA-approved oral anthelmintic drug, has broad biological activity including anticancer, antibacterial, and antiviral properties. Niclosamide has also been identified as a potent inhibitor of SARS-CoV-2 infection in vitro, generating interest in its use…
read more here.
Keywords:
cell;
mitigation niclosamide;
sars cov;
vitro evaluation ... See more keywords